Clinical Aspects and Significance of β-Chemokines, γ-Chemokines, and δ-Chemokines in Molecular Cancer Processes in Acute Myeloid Leukemia (AML) and Myelodysplastic Neoplasms (MDS)

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Oct 16

PMID 39409868

Authors

Jan Korbecki

Mateusz Bosiacki

Piotr Stasiak

Emilian Snarski

Agnieszka Brodowska

Dariusz Chlubek

Irena Baranowska-Bosiacka

Affiliations

Soon will be listed here.

Abstract

Background/objectives: Acute myeloid leukemia (AML) is a type of leukemia with a very poor prognosis. Consequently, this neoplasm is extensively researched to discover new therapeutic strategies. One area of investigation is the study of intracellular communication and the impact of the bone marrow microenvironment on AML cells, with chemokines being a key focus. The roles of β-chemokines, γ-chemokines, and δ-chemokines in AML processes have not yet been sufficiently characterized.

Methods: This publication summarizes all available knowledge about these chemotactic cytokines in AML and myelodysplastic neoplasm (MDS) processes and presents potential therapeutic strategies to combat the disease. The significance of β-chemokines, γ-chemokines, and δ-chemokines is detailed, including CCL2 (MCP-1), CCL3 (MIP-1α), CCL5 (RANTES), CCL23, CCL28, and CX3CL1 (fractalkine). Additionally, the importance of atypical chemokine receptors in AML is discussed, specifically ACKR1, ACKR2, ACKR4, and CCRL2.

Results/conclusions: The focus is on the effects of these chemokines on AML cells, particularly their influence on proliferation and resistance to anti-leukemic drugs. Intercellular interactions with non-AML cells, such as mesenchymal stem cells (MSC), macrophages, and regulatory T cells (T), are also characterized. The clinical aspects of chemokines are thoroughly explained, including their effect on overall survival and the relationship between their blood levels and AML characteristics.

References

Bazan J, Bacon K, Hardiman G, Wang W, Soo K, Rossi D . A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997; 385(6617):640-4. DOI: 10.1038/385640a0. View

Boddu P, Borthakur G, Koneru M, Huang X, Naqvi K, Wierda W . Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Front Oncol. 2018; 8:369. PMC: 6167965. DOI: 10.3389/fonc.2018.00369. View

Sander F, Nilsson M, Rydstrom A, Aurelius J, Riise R, Movitz C . Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy. Cancer Immunol Immunother. 2017; 66(11):1473-1484. PMC: 5645432. DOI: 10.1007/s00262-017-2040-9. View

Kiyoi H, Kawashima N, Ishikawa Y . FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Cancer Sci. 2019; 111(2):312-322. PMC: 7004512. DOI: 10.1111/cas.14274. View

Wu X, Li S, Chen D, Zheng G, Zhang Z, Li Z . An inflammatory response-related gene signature associated with immune status and prognosis of acute myeloid leukemia. Am J Transl Res. 2022; 14(7):4898-4917. PMC: 9360836. View

Mei C, Ren Y, Zhou X, Ye L, Ma L, Luo Y . Clinical and biological characteristics of acute myeloid leukemia with 20-29% blasts: a retrospective single-center study. Leuk Lymphoma. 2018; 60(5):1136-1145. DOI: 10.1080/10428194.2018.1515938. View

Wang Y, Zhang Y, Yang X, Han W, Liu Y, Xu Q . Chemokine-like factor 1 is a functional ligand for CC chemokine receptor 4 (CCR4). Life Sci. 2005; 78(6):614-21. PMC: 7126766. DOI: 10.1016/j.lfs.2005.05.070. View

Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976; 33(4):451-8. DOI: 10.1111/j.1365-2141.1976.tb03563.x. View

Gong Q, Zheng J, Liu W, Liu L, Li Y, Huang S . [Effect of CCL23/myeloid progenitor inhibitory factor 1 (MPIF-1) on the proliferation, apoptosis and differentiation of U937 cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007; 15(3):496-500. View

10.

Huang J, Basu S, Zhao X, Chien S, Fang M, Oehler V . Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration. Blood Cancer J. 2015; 5:e302. PMC: 4450324. DOI: 10.1038/bcj.2015.17. View

11.

Wang Y, Gao A, Zhao H, Lu P, Cheng H, Dong F . Leukemia cell infiltration causes defective erythropoiesis partially through MIP-1α/CCL3. Leukemia. 2016; 30(9):1897-908. DOI: 10.1038/leu.2016.81. View

12.

Ahn J, Kim H . mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs. Blood Res. 2022; 57(S1):32-36. PMC: 9057665. DOI: 10.5045/br.2022.2022017. View

13.

Schall T, Bacon K, Camp R, Kaspari J, Goeddel D . Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J Exp Med. 1993; 177(6):1821-6. PMC: 2191042. DOI: 10.1084/jem.177.6.1821. View

14.

Burns J, Summers B, Wang Y, Melikian A, Berahovich R, Miao Z . A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J Exp Med. 2006; 203(9):2201-13. PMC: 2118398. DOI: 10.1084/jem.20052144. View

15.

Yamamura Y, Hattori T, Obaru K, Sakai K, Asou N, Takatsuki K . Synthesis of a novel cytokine and its gene (LD78) expressions in hematopoietic fresh tumor cells and cell lines. J Clin Invest. 1989; 84(6):1707-12. PMC: 304046. DOI: 10.1172/JCI114353. View

16.

Harrison J, Rameshwar P, Chang V, Bandari P . Oxygen saturation in the bone marrow of healthy volunteers. Blood. 2002; 99(1):394. DOI: 10.1182/blood.v99.1.394. View

17.

Liu C, Lou Y, Lizee G, Qin H, Liu S, Rabinovich B . Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008; 118(3):1165-75. PMC: 2230660. DOI: 10.1172/JCI33583. View

18.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

19.

Chen D, Jiang R, Mao C, Shi L, Wang S, Yu L . Chemokine/chemokine receptor interactions contribute to the accumulation of Th17 cells in patients with esophageal squamous cell carcinoma. Hum Immunol. 2012; 73(11):1068-72. DOI: 10.1016/j.humimm.2012.07.333. View

20.

Ades L, Itzykson R, Fenaux P . Myelodysplastic syndromes. Lancet. 2014; 383(9936):2239-52. DOI: 10.1016/S0140-6736(13)61901-7. View